1. Home
  2. BCAB vs NDLS Comparison

BCAB vs NDLS Comparison

Compare BCAB & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • NDLS
  • Stock Information
  • Founded
  • BCAB 2007
  • NDLS 1995
  • Country
  • BCAB United States
  • NDLS United States
  • Employees
  • BCAB N/A
  • NDLS N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • NDLS Restaurants
  • Sector
  • BCAB Health Care
  • NDLS Consumer Discretionary
  • Exchange
  • BCAB Nasdaq
  • NDLS Nasdaq
  • Market Cap
  • BCAB 31.5M
  • NDLS 29.8M
  • IPO Year
  • BCAB 2020
  • NDLS 2013
  • Fundamental
  • Price
  • BCAB $0.79
  • NDLS $0.60
  • Analyst Decision
  • BCAB Hold
  • NDLS Buy
  • Analyst Count
  • BCAB 3
  • NDLS 2
  • Target Price
  • BCAB $1.00
  • NDLS $3.00
  • AVG Volume (30 Days)
  • BCAB 953.7K
  • NDLS 164.5K
  • Earning Date
  • BCAB 11-06-2025
  • NDLS 11-05-2025
  • Dividend Yield
  • BCAB N/A
  • NDLS N/A
  • EPS Growth
  • BCAB N/A
  • NDLS N/A
  • EPS
  • BCAB N/A
  • NDLS N/A
  • Revenue
  • BCAB $11,000,000.00
  • NDLS $494,752,000.00
  • Revenue This Year
  • BCAB N/A
  • NDLS $1.19
  • Revenue Next Year
  • BCAB N/A
  • NDLS N/A
  • P/E Ratio
  • BCAB N/A
  • NDLS N/A
  • Revenue Growth
  • BCAB N/A
  • NDLS N/A
  • 52 Week Low
  • BCAB $0.24
  • NDLS $0.55
  • 52 Week High
  • BCAB $2.53
  • NDLS $1.74
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 66.59
  • NDLS 39.67
  • Support Level
  • BCAB $0.63
  • NDLS $0.61
  • Resistance Level
  • BCAB $0.89
  • NDLS $0.69
  • Average True Range (ATR)
  • BCAB 0.07
  • NDLS 0.04
  • MACD
  • BCAB 0.00
  • NDLS 0.01
  • Stochastic Oscillator
  • BCAB 70.47
  • NDLS 23.68

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

Share on Social Networks: